Herpes simplex virus (HSV) infection of the neonate is uncommon, but genital herpes infections in adults are very common. Thus, although treating an infant with neonatal herpes is a relatively rare occurrence, managing infants potentially exposed to HSV at the time of delivery occurs more frequently. The risk of transmitting HSV to an infant during delivery is determined in part by the mother's previous immunity to HSV. Women with primary genital HSV infections who are shedding HSV at delivery are 10 to 30 times more likely to transmit the virus to their newborn infants than are women with recurrent HSV infection who are shedding virus at delivery. With the availability of commercial serological tests that reliably can distinguish type-specific HSV antibodies, it is now possible to determine the type of maternal infection and, thus, further refine management of infants delivered to women who have active genital HSV lesions. The management algorithm presented herein uses both serological and virological studies to determine the risk of HSV transmission to the neonate who is delivered to a mother with active herpetic genital lesions and tailors management accordingly. The algorithm does not address the approach to asymptomatic neonates delivered to women with a history of genital herpes but no active lesions at delivery.
"Neonatal HSV infection is typically acquired through exposure to infected maternal genital secretions during delivery. The risk of acquiring neonatal infection is influenced by several factors, including the type of maternal infection and maternal antibody status, as well as prolonged rupture of membranes and the use of fetal scalp monitoring  . Infants born to women who have a first episode genital HSV infection near term are at a much greater risk of developing neonatal HSV infection when compared to mothers with a history of recurrent HSV infection . "
[Show abstract][Hide abstract] ABSTRACT: Disseminated neonatal herpes simplex virus infection usually presents with multi-organ involvement. Untreated, this disease has a mortality rate of approximately 80%. Here, we describe a well-appearing 3-week old infant with isolated compensated hepatic failure caused by HSV-2.
[Show abstract][Hide abstract] ABSTRACT: Imagine the impact of a single substance able to reverse antibiotic resistance and to kill tumor cells without harming healthy cells. Dr. Anders Hakansson, working as a graduate student in the laboratory of Dr. Catharina Svanborg, Lund University, Sweden, was studying human milk effects
on the binding of bacterial cells to epithelial cells when he noted that a specific casein fraction of human milk blocked the binding of the bacterial cells and also affected the viability of the lung cancer cells used in the experiment.1 Further research determined that the casein protein,
alpha-lactalbumin, must be partially unfolded and then bound with a specific fatty acid found in human breast milk to become a substance now known as HAMLET: Human Alpha-lactalbumin Made LEthal to Tumor cells. Two major lines of research have evolved from these observations: use of HAMLET
in antimicrobial activity and as a tumoricidal agent.
Neonatal network: NN 07/2014; 32(4):301-8. DOI:10.1891/0730-08184.108.40.2061
[Show abstract][Hide abstract] ABSTRACT: Neonatal herpes simplex virus (HSV) infections can result in serious morbidity and mortality. Most neonatal HSV infections are caused by HSV-2, whereas the remaining cases are due to HSV-1. HSV-2 infection carries a graver prognosis than that caused by HSV-1. Many of the infections result from asymptomatic cervical shedding of virus after a primary episode of genital HSV in the third trimester. Of all the HSV infections, neonatal HSV infection should be the most amenable to prevention and treatment because it is acquired most often at birth rather than early in gestation. High dose of intravenous acyclovir forms the mainstay of treatment in neonatal HSV. Advances in the diagnosis and management of neonatal HSV disease have resulted in reduction of mortality in patients with disseminated disease from 85% to 29% and from 50% to 4% with central nervous system disease.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.